Literature DB >> 28034624

Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.

David S Goldstein1, Patti Sullivan2, Courtney Holmes2, Deborah C Mash3, Irwin J Kopin2, Yehonatan Sharabi4.   

Abstract

BACKGROUND: Severe putamen dopamine depletion characterizes Parkinson's disease (PD) and multiple system atrophy (MSA). The extent of the depletion is greater than can be accounted for by loss of nigrostriatal dopaminergic terminals alone. We used putamen tissue levels and ratios of cysteinyl and parent catechols to explore possible denervation-independent abnormalities of dopamine synthesis and fate in PD and MSA. 5-S-Cysteinyldopa (Cys-DOPA) is produced from spontaneous oxidation of DOPA and 5-S-cysteinyldopamine (Cys-DA) from spontaneous oxidation of DA.
METHODS: Post-mortem putamen tissue samples from 17 PD and 25 MSA patients and 30 controls were assayed for endogenous catechols including DA, its cytoplasmic metabolites (Cys-DA, 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylethanol, and 3,4-dihydroxyphenylacetaldehyde), and tyrosine hydroxylation products proximal to DA (DOPA and Cys-DOPA).
RESULTS: The PD and MSA groups did not differ in mean values of parent or cysteinyl catechols, and the data for the two groups were lumped. In the patients an index of vesicular storage of DA (the ratio of DA to the sum of its cytoplasmic metabolites) averaged 54% of control (p = 0.001), and an index of L-aromatic-amino-acid decarboxylase (LAAAD) activity (the ratio of DA and the sum of its cytoplasmic metabolites to the sum of DOPA + Cys-DOPA) averaged 21% of control (p < 0.0001). An index of innervation (the sum of DOPA + Cys-DOPA) averaged 63% of control (p = 0.01).
INTERPRETATION: Based on patterns of parent and cysteinyl catechols in putamen, PD and MSA involve decreased vesicular uptake and decreased LAAAD activity in the residual dopaminergic terminals. The combination seems to contribute importantly to dopamine depletion in these diseases.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cysteinyl-DOPA; Cysteinyl-dopamine; Multiple system atrophy; Parkinson’s disease

Mesh:

Substances:

Year:  2016        PMID: 28034624      PMCID: PMC6319359          DOI: 10.1016/j.parkreldis.2016.12.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

2.  N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Yehonatan Sharabi
Journal:  Neurochem Res       Date:  2017-08-24       Impact factor: 3.996

Review 3.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

4.  3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing α-Synuclein.

Authors:  Yunden Jinsmaa; Risa Isonaka; Yehonatan Sharabi; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2019-11-19       Impact factor: 4.030

Review 5.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

6.  Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases.

Authors:  David S Goldstein; Mark J Pekker; Graeme Eisenhofer; Yehonatan Sharabi
Journal:  JCI Insight       Date:  2019-07-23

Review 7.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

8.  The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.

Authors:  Regev Landau; Reut Halperin; Patti Sullivan; Zion Zibly; Avshalom Leibowitz; David S Goldstein; Yehonatan Sharabi
Journal:  Dis Model Mech       Date:  2022-01-24       Impact factor: 5.758

9.  Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition.

Authors:  Elizabeth A Disbrow; Nathaniel D Glassy; Elizabeth M Dressler; Kimberley Russo; Elizabeth A Franz; Robert S Turner; Maria I Ventura; Leighton Hinkley; Richard Zweig; Srikantan S Nagarajan; Christina R Ledbetter; Karen A Sigvardt
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

10.  Altered Spontaneous Neural Activity and Functional Connectivity in Parkinson's Disease With Subthalamic Microlesion.

Authors:  Bei Luo; Yue Lu; Chang Qiu; Wenwen Dong; Chen Xue; Li Zhang; Weiguo Liu; Wenbin Zhang
Journal:  Front Neurosci       Date:  2021-07-20       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.